Psychedelics for Alcoholism

Live Q&A Panel with Clearmind's Management

December 8, 2021

Clearmind’s Management Answers Questions Related to the Potential Treatment for Alcohol Use Disorder and Binge Drinking Based on Its Psychoactive Molecule MEAI


Adi Zuloff-Shani, PhD

Clearmind's Chief Executive Officer

Dr. Adi Zuloff-Shani is a Biomedical Research and Development Executive with over 20 years of strategic and operational leadership in the healthcare industry and a deep understanding of therapeutics development in heavily regulated environments.

Adjunct Prof. Mark Haden

Clearmind's VP of Business Development

Previously the Executive Director of MAPS Canada for 10 years, Mark is an adjunct professor at the University of British Columbia School of Population and Public Health, and has published on the issue of drug control policy and psychedelics. Mark also worked in the addictions field in counselling, supervisory and management positions for 28 years.


Shannon Smadella

Clearmind's Community Development

Shannon has interviewed some of the most prominent leaders, innovators, scientists, doctors and luminaries in the psychedelic space. She was the host of Seasons 1 & 2 of ‘Examining The Psychedelic Renaissance’ with MAPS Canada. Shannon has researched, observed, coached and trained in excess of 5,000 individuals in sales, marketing, and business management and continues to help people through her company Insight Global, and enjoys interviewing leaders in the health and wellness field through her podcast ‘Dialed In’.